Promising results after the implant of CEB-01, currently in Clinical Phase
In August 2020, CEB-01 was implanted in a first patient with retroperitoneal soft tissue sarcoma at the Hospital de la Santa Creu i Sant Pau (Barcelona) under the clinical study led by Dr. Pousa.
Eight weeks after the procedure, no adverse events have been detected, nor post-surgical complications and/or toxicity linked to the product developed by Cebiotex.
There are currently two precandidates under evaluation for their inclusion in the study CEB-01-RLS01-CT.
